Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited

Executive Summary

The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8

You may also be interested in...

Reverse Payment Settlements Suffer Reversal Of Fortune At Third Circuit

FTC ends its losing streak on patent settlement suits as the Third Circuit says “rule of reason” rather than “scope of patent” analysis should be applied to brand/generic settlements; appeals court reinstates suit by direct purchasers challenging Schering’s payments to Upsher-Smith and ESI Lederle.

FTC Tries Again On K-Dur; Joins Pharmacies, DoJ In Appeal Of Reverse Settlement Case

Strength of patent is a focus of FTC's amicus brief; the Commission acknowledges that it has inappropriately ignored the issue in the past.

Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver

Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts